


## CLAIMS

1. A pharmaceutical composition used for the treatment of malaria comprising the compound of the general formula:



5

(wherein R<sub>1</sub>~R<sub>12</sub> is independently hydrogen atom, halogen atom, hydroxyl group, alkyl group, alkoxy group, amino group or acylamino group)

and a pharmaceutically acceptable carrier.

10 2. A pharmaceutical composition of Claim 1 wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, and R<sub>12</sub> is hydrogen atom in the compound.

15 3. A pharmaceutical composition of Claim 2 wherein the compound is 2S, 3R, 2'S- 5,7,5',7'-tetrahydroxy-2,2'-bis-(4-hydroxyphenyl)-2,3,2',3'-tetrahydro-[3,8']bichromenyl-4,4'-dione.

4. A pharmaceutical composition of Claim 1 wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, and R<sub>12</sub> is hydrogen atom and R<sub>11</sub> is hydroxyl group in the compound.

5. A pharmaceutical composition of Claim 4 wherein the compound is 2S,3R,2'S,3'R-5,7,3',5',7'-pentahydroxy-2,2'-bis-(4-hydroxyphenyl)-2,3,2',3'-tetrahydro-[3,8']bichromenyl-4,4'-dione.

5 6. A pharmaceutical composition of Claim 4 wherein the compound is 2R,3S,2'S,3'R-5,7,3',5',7'-pentahydroxy-2,2'-bis-(4-hydroxyphenyl)-2,3,2',3'-tetrahydro-[3,8']bichromenyl-4,4'-dione.

7. A pharmaceutical composition of Claim 1 wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>9</sub>, R<sub>10</sub>, and R<sub>12</sub> is hydrogen atom and R<sub>8</sub> and R<sub>11</sub> is hydroxyl group.

8. A pharmaceutical composition of Claim 7 wherein the compound is 2S,3R,2'S,3'R-2'-(3,4-dihydroxyphenyl)-5,7,3',5',7'-pentahydroxy-2-(4-hydroxyphenyl)-2,3,2',3'-tetrahydro-[3,8']bichromenyl-4,4'-dione.